Targeting the transcription factor GATA3 by the DNAzyme formulation SB012 in patients with moderately-to-severely active ulcerative colitis: a multicenter, randomized, placebo-controlled, phase 2a induction trial.
已完结
10
由 何曼慈 发布于 2026/6/17 15:55:45
DOI:10.1093/ibd/izag046
作者：Raja Atreya,?Tanja Kühbacher,?Michael Vieth,?Andre Jefremow,?Simon Hirschmann,?Maximilian J Waldner,?Sarah Fischer,?Marcel Vetter,?Oliver Drvarov,?Benno Weigmann,?Michael Meyer,?Tanja Mühl,?Ursula H
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1093/ibd/izag046
作者：Raja Atreya,?Tanja Kühbacher,?Michael Vieth,?Andre Jefremow,?Simon Hirschmann,?Maximilian J Waldner,?Sarah Fischer,?Marcel Vetter,?Oliver Drvarov,?Benno Weigmann,?Michael Meyer,?Tanja Mühl,?Ursula H
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1093/ibd/izag046
Oxford University Press
其它数据库
Elsevier
京公网安备 11010802042870号
